Should all patients starting on ADT be on a statin too?

A newly published article in JAMA Oncology has now suggested that adding a statin to a patient’s treatment regimen at initiation of androgen deprivation therapy (ADT) may significantly impact time to disease progression among men diagnosed with progressive, hormone-sensitive prostate cancer. … READ MORE …

Does sequencing of therapy affect outcomes of treatment with sipuleucel-T + ADT in high-risk disease?

We still have very little knowledge about whether early prostate cancer immunotherapy with sipuleucel-T (Provenge) or other forms of immunotherapy might be beneficial in the management of patients with high-risk prostate cancer. … READ MORE …

Prostvac-type vaccine therapy in progressive prostate cancer after first-line therapy

A study just published in European Urology has suggested that early therapy with Prostvac-type vaccines might have value in the management of men with a rising PSA after first-line therapy. … READ MORE …

Global Phase III trial of enzalutamide in progressive, high-risk prostate cancer

According to a joint media release from Medivation and Astellas earlier today, the companies will soon be initiating an important and major new trial of enzalutamide in men with progressive prostate cancer after first-line therapy. … READ MORE …

Second-line therapy for progressive, high-risk prostate cancer: time for a STAMPEDE-like trial?

Let’s say you are 58 years of age, in apparently excellent health for your age, when you get diagnosed with high-risk prostate cancer, based on a Gleason score of 4 + 4 = 8, a PSA level of 3.7, and a clinical stage of T1c, with 4/12 biopsy cores positive for cancer. … READ MORE …

Disulfiram in prostate cancer revisited (this time with copper supplementation)

Not so long ago (back in late 2013), Schweizer et al. reported data from a very small trial of an old drug called disulfiram (also known as Antabuse) in the treatment of men with progressive prostate cancer after first-line therapy. … READ MORE …

Current and future imaging techniques and recurrent prostate cancer

An article just reproduced on the Medscape Oncology web site provides a very readable review of what the authors describe as, “A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer”. … READ MORE …